Quantcast
Channel: Latest Crohn's Disease News on BioPortfolio
Viewing all articles
Browse latest Browse all 2985

Galapagos begins DIVERSITY Phase III study of filgotinib to treat Crohns disease

$
0
0
Belgiumbased clinicalstage biotechnology company Galapagos has begun its DIVERSITY Phase III study of filgotinib to treat Crohns disease CD.

Viewing all articles
Browse latest Browse all 2985

Trending Articles